To assess the feasibility and safety of cellular immunotherapy utilizing ex vivo expanded autologous CD8-positive T cell clones genetically modified to express the IL-13 zetakine chimeric immunoreceptor and the Hy/TK selection/suicide fusion protein in patients with recurrent or refractory, high-grade malignant glioma. This evidence concerns the gene CD8A and malignant glioma.